-
Mashup Score: 3MYTHOS: trastuzumab deruxtecan in HER2+ salivary gland cancer - 17 hour(s) ago
Ichiro Kinoshita, MD, PhD, Hokkaido University Hospital, Sapporo, Japan, discusses findings from the Phase II MYTHOS trial (jRCT2011210017), evaluating trastuzumab deruxtecan (T-DXd) in HER2-positive recurrent/metastatic salivary gland cancer. The study showed an encouraging objective response rate and common grade 3/4 adverse events included neutropenia and lymphopenia, with manageable interstitial lung disease. These promising results support T-DXd as a potential therapeutic option for this rare cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
Luigi Lorini, MD, Humanitas Research Hospital, Rozzano, Italy, comments on the findings of the CONCORDL-1 study, which retrospectively analyzes PD-L1 expression concordance between primary and recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Whilst results from the KEYNOTE-048 trial (NCT02358031) highlighted the relevance of PD-L1 Combined Positive Score (CPS) as a predictive biomarker for checkpoint inhibitors, findings from this study showed that clinical-pathological variables had no significant impact on concordance. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥Luigi Lorini, MD, discusses the CONCORDL-1 study on PD-L1 expression concordance in HNSCC. Results show clinical-pathological variables had no significant impact on concordance: ➡️https://t.co/3Psnaspdl7⬅️ @myESMO #ESMO24 #ImmunoOnc
-
-
Mashup Score: 17KEYNOTE-811: final OS results of pembrolizumab, trastuzumab and chemotherapy in G/GEJ - 29 day(s) ago
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the final overall survival (OS) analysis of the Phase III KEYNOTE-811 study (NCT03615326), which assessed first-line pembrolizumab with trastuzumab and chemotherapy in patients with unresectable, HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJ). The combination significantly improved OS and progression-free survival (PFS) compared to placebo plus trastuzumab and chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@YJanjigianMD of @MSKCancerCenter discusses the final OS analysis of the Phase III KEYNOTE-811 study, showing that 1L pembrolizumab with trastuzumab and chemo significantly improves OS in HER2+ mG/GEJ cancer: ➡️https://t.co/S8VrmkISEE⬅️ #ESMO24 @myESSMO #ImmunoOnc
-
🎥Ichiro Kinoshita, MD, PhD, of @HokkaidoUni highlights promising Phase II MYTHOS trial results: T-DXd shows strong efficacy in HER2+ metastatic salivary gland cancer, with manageable side effects: ➡️https://t.co/j5OU5YMt3e⬅️ @mESMO #ESMO24 #ImmunoOnc